" class="no-js "lang="en-US"> Life Line Screening Appoints Matt Miller as Chief Executive Officer
Thursday, March 23, 2023

Life Line Screening Appoints Matt Miller as Chief Executive Officer

Life Line Screening, a leading mobile preventative health screening company, announces the appointment of Matt Miller to serve as Chief Executive Officer. This announcement comes as Life Line Screening is undergoing expansion of its product offering and customer services to better serve local communities across North America.

Mark Hanley, Chairman of Life Line Screening stated, “We are pleased to have Matt Miller join Life Line Screening as we enter into an exciting time of growth to better serve our customers with important information about their personal vascular health, stroke prevention, and more, and to continue to expand our relationships with our key business partners to deliver beneficial services.”

Matt brings a wealth of knowledge in technology, clinical drug development, and patient experience expertise from his experience at StudyKIK, where he was co-founder & CEO. StudyKIK is a leading Patient Recruitment & Technology Company which fundamentally streamlined the way people joined and participated in clinical trials around the world. The experience he brings to Life Line Screening will be paramount as the company undergoes expansion in services to provide the best possible preventative health experience for all its customers.

“I am focused on unlocking even more potential of Life Line Screening’s mission to provide lifesaving preventative health information to people through our innovative community screening events covering vascular health, stroke risk, metabolic disease understanding, and much more. I am honored to join such an innovative team as we work together to grow these important services through therapeutic expansion and technology,” said Matt Miller, CEO of Life Line Screening.

  1. OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Read more
  2. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
  3. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
  4. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
  5. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more